Rhelion Life Sciences, through its subsidiary Filament Health, received a new Canadian patent for its natural psilocybin drug candidate PEX010. This patent enhances the company's extensive global intellectual property portfolio, which covers extraction, purification, and standardized dosing of psilocybin. PEX010 supports over 80 research studies worldwide and is produced using proprietary methods ensuring consistent quality. The company plans to introduce a 0.5 mg dose alongside existing doses, strengthening its position in the legal psychedelic drug market.
Rhelion Life Sciences' recent Canadian patent news is presented here with Pluang's Health sector market snapshot as of Sep 22, 2026 18:11 WIB: Among 95 priced US Health-sector stocks, 50 rose and 38 fell. CTXR traded at USD 0.59 with a 1-day gain of 2.91% and a typical hold time of 16 days, contrasting with LLY priced at USD 1,144.00 which fell 1.75% and sees a much longer typical hold time of 93 days, alongside a Pluang order activity skewed 66% to sell.
Viscount Mining's 2026 drilling at the Silver Cliff Project in Colorado found significant silver and gold mineralization beyond the current Kate Silver Resource boundary, with some holes showing very high grades, including 1,030 g/t silver and 10.20 ...
GoGold Resources is progressing well with construction at its Los Ricos South project in Jalisco, Mexico, with over 150 contractors on site and all major equipment orders placed. The project remains on schedule for its first silver pour in the second...
Novo Nordisk held its investor day in London, outlining its strategy for growth after its key obesity drugs lose patent protection. Despite plans for multiple new blockbusters and expansion into heart and liver disease treatments, analysts were unimp...
YYForce Inc. announced its 2030 Vision to create an integrated workforce ecosystem combining human staffing, AI, humanoid robots, and smart facility management. The strategy aims to enhance industries like hospitality, healthcare, logistics, and reta...
The iShares Semiconductor ETF (SOXX) is rated a Buy at around $533 per share, based on expectations of continued strong earnings growth in the semiconductor industry rather than relying on price-to-earnings (P/E) multiple expansion. The analyst's con...
